Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edesa Biotech Inc (NQ: EDSA )

2.300 +0.090 (+4.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech Inc

< Previous 1 2 3 4 5 Next >
What Is Going on With Edesa Biotech (EDSA) Stock Today?
Edesa Biotech released encouraging Phase 2 results for its respiratory-syndrome-targeting antibody, thus initially boosting EDSA stock. 
Via InvestorPlace
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
Via ACCESSWIRE
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
Via ACCESSWIRE
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
Via ACCESSWIRE
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
Via ACCESSWIRE
Edesa Biotech Adds Mechanically Ventilated Patients To Late-Stage COVID-19 Study
Via Benzinga
Recap: Edesa Biotech Q4 Earnings
Edesa Biotech (NASDAQ:EDSA) reported its Q4 earnings results on Tuesday, December 28, 2021 at 04:15 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference
Via ACCESSWIRE
Edesa Biotech to Present at ARDS Drug Development Summit
TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par... 
From Edesa Biotech
Via AccessWire
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 87 companies hit new 52-week lows. 
Via Benzinga
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the... 
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par... 
From Edesa Biotech
Via AccessWire
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial... 
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Edesa Biotech
Via AccessWire
Edesa Biotech Appoints Strategy Expert to Board of Directors
TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the... 
From Edesa Biotech
Via AccessWire
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the... 
From Edesa Biotech
Via AccessWire
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it... 
From Edesa Biotech
Via AccessWire
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an... 
From Edesa Biotech
Via AccessWire
Exposures COVID-19
66 Biggest Movers From Yesterday
Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement. Forge Global... 
Via Benzinga
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported... 
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Edesa Biotech to Join Ontario Bioscience Panel Discussion
TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr.... 
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy
Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically... 
Via Benzinga
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
- Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a... 
From Edesa Biotech
Via AccessWire
Exposures COVID-19
5 Stocks To Watch For Wednesday, December 29, 2021
5 stocks you that you should keep in mind today. 
Via Talk Markets
5 Stocks To Watch For December 29, 2021
Some of the stocks that may grab investor focus today are: Cal-Maine Foods (NASDAQ: CALM) reported weaker-than-expected earnings for its second quarter on Tuesday. Cal-Maine... 
Via Benzinga
Edesa Biotech Reports Fiscal Year 2021 Results
TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported... 
From Edesa Biotech
Via AccessWire
Exposures COVID-19
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Edesa Biotech Extends COVID-19 Clinical Study to Poland
- Expansion to European Union country follows favorable Phase 2 results - Company focusing on critically ill hospitalized patients TORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc.... 
From Edesa Biotech
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021
Upgrades According to Keefe, Bruyette & Woods, the prior rating for Old National Bancorp (NASDAQ:... 
Via Benzinga
Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions
Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.